Abstract |
In a double-blind study, we compared the final outcome of 99 Bell's palsy patients treated with either acyclovir- prednisone (53 patients) or placebo- prednisone (46 patients). For patients receiving acyclovir, the dosage was 2,000 mg (400 mg 5 times daily) for 10 days. Electrical tests included electroneurography and the maximal stimulation test. Univariate comparisons of outcome and electrical tests between the two groups were made with chi 2 analysis, Fisher's exact test, and t-tests. The outcome in acyclovir- prednisone-treated patients was superior to that in placebo- prednisone-treated patients. Treatment with acyclovir- prednisone was statistically more effective in returning volitional muscle motion (recovery profile of 10; p = .02) and in preventing partial nerve degeneration (p = .05) than placebo- prednisone treatment. The t-tests indicated that the recovery profile and index means were significantly better for the acyclovir-treated group (recovery profile t = 1.99, p = .051; recovery index t = 2.10, p = .040). We conclude that acyclovir- prednisone is superior to prednisone alone in treating Bell's palsy patients and suggest that herpes simplex is the probable cause of Bell's palsy.
|
Authors | K K Adour, J M Ruboyianes, P G Von Doersten, F M Byl, C S Trent, C P Quesenberry Jr, T Hitchcock |
Journal | The Annals of otology, rhinology, and laryngology
(Ann Otol Rhinol Laryngol)
Vol. 105
Issue 5
Pg. 371-8
(May 1996)
ISSN: 0003-4894 [Print] United States |
PMID | 8651631
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Prednisone
- Acyclovir
|
Topics |
- Acyclovir
(administration & dosage, therapeutic use)
- Adult
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Drug Therapy, Combination
- Facial Paralysis
(drug therapy, etiology, virology)
- Female
- Humans
- Male
- Middle Aged
- Prednisone
(administration & dosage, therapeutic use)
- Simplexvirus
(pathogenicity)
|